Page 1 | Search Results | Blood | American Society of Hematology

1-5 of 5

Sort by

Sort Order Select

Journal Articles

A prospective multi-institutional study of eculizumab to treat high-risk stem cell transplantation–associated TMA

Sonata Jodele, Christopher E. Dandoy, Paibel Aguayo-Hiraldo, Adam Lane, Ashley Teusink-Cross, Anthony Sabulski, Kana Mizuno, Benjamin L. Laskin, Jason Freedman, Stella M. Davies

Blood (2024) 143 (12): 1112–1123.

https://doi.org/10.1182/blood.2023022526

Published: 2024

Includes: Supplemental data

Journal Articles

A randomized phase 2 trial of oral vitamin A for graft-versus-host disease in children and young adults

Pooja Khandelwal, Lucille Langenberg, Nathan Luebbering, Kelly E. Lake, Abigail Butcher, Kylie Bota, Kristie N. Ramos, Cynthia Taggart, Hannah Choe, Sumithira Vasu, Ashley Teusink-Cross, Jane Koo, Gregory Wallace, Lindsey Romick-Rosendale, Miki Watanabe-Chailland, David B. Haslam, Adam Lane, Stella M. Davies

Blood (2024) 143 (12): 1181–1192.

https://doi.org/10.1182/blood.2023022865

Published: 2024

Includes: Supplemental data

Journal Articles

Emapalumab for Treatment of Impending Graft Failure

Anthony Sabulski, Sonata Jodele, Eleanor Cook, Kasiani Myers, Adam C. Lane, Samppa Ryhanen, Sr., Maria Pia Cefalo, Francesco Quagliarella, Stella M Davies, Ashley Teusink-Cross, Paibel Aguayo-Hiraldo, Jessie L. Alexander, Paul Szabolcs, Mira Kohorst, Tiziana Corsetti, Franco Locatelli, Pietro Merli

Blood (2023) 142 (Supplement 1): 114.

https://doi.org/10.1182/blood-2023-181096

Published: 2023

Journal Articles

Complement blockade for TA-TMA: lessons learned from a large pediatric cohort treated with eculizumab

Sonata Jodele, Christopher E. Dandoy, Adam Lane, Benjamin L. Laskin, Ashley Teusink-Cross, Kasiani C. Myers, Gregory Wallace, Adam Nelson, Jack Bleesing, Ranjit S. Chima, Russel Hirsch, Thomas D. Ryan, Stefanie Benoit, Kana Mizuno, Mikako Warren, Stella M. Davies

Blood (2020) 135 (13): 1049–1057.

https://doi.org/10.1182/blood.2019004218

Published: 2020

Includes: Supplemental data

Journal Articles

JAK1/2 Inhibition As a Salvage Therapy for Steroid Refractory Acute and Chronic Graft Versus Host Disease in Pediatric Allogeneic Hematopoietic Stem Cell Transplant Recipients

Pooja Khandelwal, MD, Ashley Teusink-Cross, PharmD, Adam S. Nelson, MBBS, Christopher E. Dandoy, MD, Javier A. El-Bietar, MD, Rebecca A Marsh, MD, Ashish R Kumar, MBBS, PhD, Michael S Grimley, MD, Sonata Jodele, MD, Stella M Davies, MBBS, PhD, Kasiani C. Myers, MD

Blood (2016) 128 (22): 4568.

https://doi.org/10.1182/blood.V128.22.4568.4568

Published: 2016

NARROW

A prospective multi-institutional study of eculizumab to treat high-risk stem cell transplantation–associated TMA

A randomized phase 2 trial of oral vitamin A for graft-versus-host disease in children and young adults

Emapalumab for Treatment of Impending Graft Failure

Complement blockade for TA-TMA: lessons learned from a large pediatric cohort treated with eculizumab

JAK1/2 Inhibition As a Salvage Therapy for Steroid Refractory Acute and Chronic Graft Versus Host Disease in Pediatric Allogeneic Hematopoietic Stem Cell Transplant Recipients

Email alerts

ASH Publications

American Society of Hematology

A prospective multi-institutional study of eculizumab to treat high-risk stem cell transplantation–associated TMA

A randomized phase 2 trial of oral vitamin A for graft-versus-host disease in children and young adults

Emapalumab for Treatment of Impending Graft Failure

Complement blockade for TA-TMA: lessons learned from a large pediatric cohort treated with eculizumab

JAK1/2 Inhibition As a Salvage Therapy for Steroid Refractory Acute and Chronic Graft Versus Host Disease in Pediatric Allogeneic Hematopoietic Stem Cell Transplant Recipients

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only